

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



## RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/798,096

Source: EFWD

Date Processed by STIC: 3/22/04

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT

MARK SPENCER, TELEPHONE: 703-308-4212; FAX: 703-308-4221

Effective 12/13/03: TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER  
VERSION 4.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND  
TRADEMARK OFFICE WEBSITE SEE BELOW FOR ADDRESS

<http://www.uspto.gov/web/offices/pac/checker/chkr41note.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses.

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 1450
3. Hand Carry directly to (EFFECTIVE 12/01/03):  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,  
2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,  
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 10/08/03

## Raw Sequence Listing Error Summary

### ERROR DETECTED

### SUGGESTED CORRECTION

SERIAL NUMBER: 10798,096

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 ☐ **Wrapped Nucleics  
Wrapped Aminos** The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
  
- 2 ☐ **Invalid Line Length** The rules require that a line not exceed 72 characters in length. This includes white spaces.
  
- 3 ☐ **Misaligned Amino  
Numbering** The numbering under each 5<sup>th</sup> amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
  
- 4 ☒ **Non-ASCII** The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
  
- 5 ☐ **Variable Length** Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
  
- 6 ☐ **PatentIn 2.0  
"bug"** A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s). Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
  
- 7 ☐ **Skipped Sequences  
(OLD RULES)** Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:  
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
(i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)  
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
This sequence is intentionally skipped  
  
Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
  
- 8 ☐ **Skipped Sequences  
(NEW RULES)** Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence.  
<210> sequence id number  
<400> sequence id number  
000
  
- 9 ☐ **Use of n's or Xaa's  
(NEW RULES)** Use of n's and/or Xaa's have been detected in the Sequence Listing.  
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.  
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
  
- 10 ☐ **Invalid <213>  
Response** Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
  
- 11 ☐ **Use of <220>** Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses.  
Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.  
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
  
- 12 ☐ **PatentIn 2.0  
"bug"** Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
  
- 13 ☐ **Misuse of n/Xaa** "n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid



## SEQUENCE LISTING

10/998,096 Page 1

&lt;110&gt; Rea-Min Chu

Ching-Yi Lin

Ya-Wen Hsiao

Kuang-Wen Liao

Submitted file  
could not be processed  
due to numerous errors

&lt;120&gt; COMPLEX IMMUNO-GENE MEDICAL COMPOSITION FOR INHIBITING TUMOR CELLS

&lt;160&gt;4

&lt;210&gt;1

&lt;211&gt;636

&lt;212&gt; mRNA and PRT

&lt;213&gt; Human

&lt;220&gt;

&lt;221&gt; IL-6

delete, mandatory, <212> has to be either  
DNA, RNA or PRT, if  
it is both DNA/RNA  
please use type DNA  
and explain in section  
<220>-<223>.

&lt;300&gt;

&lt;308&gt; NCBI pubmed Genbank ; Accession No. : NM 000600

<309> ← please insert, mandatory, if <308> is shown  
then <309> must  
be inserted  
with resp

&lt;400&gt;1

63	atg aac tcc ttc tcc	78	aca agc gcc ttc	93	ggc cca ggt gcc tcc	108	ctg ggg ctg ctg
1	Met Asn Ser Phe Ser	5	Thr Ser Ala Phe	10	Pro Val Ala Phe	15	Leu Gly Leu Leu
123	gtg ttg cct gct gcc	138	ttc cct gcc cca	153	gta ccc cca gga	168	gat tcc aaa gat
1	Val Leu Pro Ala Ala	25	Phe Pro Ala Pro	30	Val Pro Pro Gly	35	Glu Asp Lys Asp
183	gcc cca cac aga cag	198	cca ctc acc tct	213	tea gaa cga att	228	gac aaa caa att
1	Ala Pro His Arg Gln	45	Pro Leu Thr Ser	50	Glu Arg Ile Asp	55	Lys Gln Ile Arg
243	ctc gac ggc atc tca	258	gcc ctg aga aag	273	gag aca tgt aac	288	aag agt aac atg
1	Leu Asp Gly Ile Ser	65	Ala Leu Arg Lys	70	Glu Thr Cys Asn	75	Lys Ser Asn Met
303	agc aaa gag gca ctg	318	gca gaa aac aac	333	ctg aac ctt cca	348	aag atg gct gaa
1	Ser Lys Glu Ala Leu	85	Ala Glu Asn Asn	90	Leu Asn Leu Pro	95	Lys Met Ala Glu
363	ttc caa tct gga ttc	378	aat gag gag act	393	tgc ctg gtg aaa	408	atc atc act ggt
1	Cys Phe Gln Ser Gly	105	Phe Asn Glu Glu	110	Thr Cys Leu Val	115	Lys Ile Ile Thr
423		438		453		468	

← please  
see id  
# 4  
on er  
Summe  
Sheet

gag	ttt	gag	gta	tac	cta	cag	tac	ctc	cag	aac	aga	ttt	gag	agt	agt	gag	gaa	caa	gcc	420	
Glu	Phe	Glu	Val	Tyr	Leu	Glu	Tyr	Leu	Gln	Asn	Arg	Phe	Glu	Ser	Ser	Glu	Glu	Gln	Ala	140	
				125					130					135							
483	aga	gct	gtg	cag	atg	agt	acu	aaa	gtc	ctg	atc	cag	ttc	ctg	cag	aaa	aag	gca	aag	aat	480
	Arg	Ala	Val	Gln	Met	Ser	Thr	Lys	Val	Leu	Ile	Gln	Phe	Leu	Gln	Lys	Lys	Ala	Lys	Asn	160
				145						150				155							
543	cta	gat	gca	ata	acc	acc	cct	gac	cca	acc	aca	aat	gcc	agc	ctg	ctg	acg	aag	ctg	cag	540
	Leu	Asp	Ala	Ile	Thr	Thr	Pro	Asp	Pro	Thr	Thr	Asn	Ala	Ser	Leu	Leu	Thr	Lys	Leu	Gln	180
				165						170					175						
603	gca	cag	aac	cag	igg	ctg	cag	gac	atg	aca	act	cat	ctc	att	ctg	cgc	agc	ttt	aag	gag	600
	Ala	Gln	Asn	Gln	Trp	Leu	Gln	Asp	Met	Thr	Thr	His	Leu	Ile	Leu	Arg	Ser	Phe	Lys	Glu	200
				185						190					195						
663	ttc	ctg	cag	tcg	agc	ctg	agg	gct	ctt	cgg	caa	atg									
	Phe	Leu	Gln	Ser	Ser	Leu	Arg	Ala	Leu	Arg	Gln	Met			636						
				205						210											

delete, see  
item #4  
on  
error  
summary  
sheet

<210>2

<211>60

<212>mRNA and PRT

<213>Human

<221>IL-2 Signal Peptide

<300>

<308>NCBI pubmed Genbank : (Accession No. : V00564)

<309> insert with response

<400>2

atg	tac	agg	atg	caa	ctc	ctg	tct	tgc	att	gca	cta	agt	ctt	gca	ctt	gtc	aca	aac	agt	60
Met	Tyr	Arg	Met	Gln	Leu	Leu	Ser	Cys	Ile	Ala	Leu	Ser	Leu	Ala	Leu	Val	Thr	Asn	Ser	
1				5					10					15					20	

<210>3

<211>342

<212>mRNA and PRT

<213>Human

<221>Partial Sequence Encoding Human IL-15

<300>

delete, same error

delete

please insert

please move to section <223>

Accession No. : U14407

same error

13097 ← pls insert

aac Asn 1	tgg Trp	gtg Val	aat Asn	gta Val 5	ata Ile	agt Ser	gat Asp	tgg Leu	aaa Lys 10	aaa Lys	att Ile	gaa Glu	gat Asp	ctt Leu 15	att Ile	caa Gln	tct Ser	atg Met	cat His 20	60
att Ile	gat Asp	gct Ala	act Thr	tta Leu 25	tat Tyr	acg Thr	gaa Glu	agt Ser	gat Asp 30	gtt Val	cac His	ccc Pro	agt Ser	tgc Cys 35	aaa Lys	gta Val	aca Thr	gca Ala	atg Met 40	120
aag Lys	tgc Cys	ttt Phe	ctc Leu	ttg Leu 45	gag Glu	tta Leu	caa Gln	gtt Val 50	att Ile	tca Ser	ctt Leu	gag Glu	tcc Ser	gga Gly 55	gat Asp	gca Ala	agt Ser	att Ile	cat His 60	180
gat Asp	aca Thr	gtt Val	gaa Glu	aat Asn 65	ctg Leu	atc Ile	atc Ile	cta Leu	gca Ala 70	aac Asn	aac Asn	agt Ser	tig Leu	tct Ser 75	tct Ser	aat Asn	ggg Gly	aat Asn	gta Val 80	240
aca Thr	gaa Glu	tct Ser	gga Gly	tgc Cys 85	aaa Lys	gaa Glu	tgt Cys	gag Glu	gaa Glu 90	ctg Leu	gag Glu	gaa Glu	aaa Lys	aat Asn 95	att Ile	aaa Lys	gaa Glu	ttt Phe	tgg Leu 100	300
cag Gln	agt Ser	ttt Phe	gta Val	cat His 105	att Ile	gtc Val	caa Gln	atg Met	ttc Phe 110	atc Ile	aac Asn	act Thr	tct Ser	342						

**<211>402**

<212> mRNA and PRT

<213> Artificial Chimeric Sequence

<220>

<221> IL-2SP/IL-15MP

**<223> Artificial Chimeric Sequence Encoding IL-2SP/IL-15MP**

<300>

<308>NCBI pubmed Genbank / IL-2 Accession No. : V00564

IL-15 Accession No. : U14407

please insert  
dates for each  
accession No.

: 400 > 4

alg tac agg atg caa ctc ctg tct tgc att gca cta agt ctt gca ctt gtc aca aac agt 60  
 Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser  
 1 5 10 15 20  
 Sequence encoding IL-2 signal peptide

aac tgg gtg aat gta ata agt gat tlg aaa aaa att gaa gat ctt att caa tct atg cat 120  
Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile Gln Ser Met His  
25 30 35 40

att Ile	gat Asp	gct Ala	act Thr	tta Leu 45	tat Tyr	acg Thr	gaa Glu	agt Ser	gat Asp 50	ggt Val	cac His	ccc Pro	agt Ser	tgc Cys 55	aaa Lys	gta Val	aca Thr	gca Ala	atg Met 60	180
aag Lys	tgc Cys	ttt Phe	ctc Leu	ttg Leu 65	gag Glu	tta Leu	caa Gln	ggt Val	att Ile 70	tca Ser	ctt Leu	gag Glu	tcc Ser	gga Gly 75	gat Asp	gca Ala	agt Ser	att Ile	cat His 80	240
gat Asp	aca Thr	gta Val	gaa Glu	aat Asn 85	ctg Leu	atc Ile	atc Ile	cta Leu	gca Ala 90	aac Asn	aac Asn	agt Ser	ttg Leu	tct Ser 95	tct Ser	aat Asn	ggg Gly	aat Asn	gta Val 100	300
aca Thr	gaa Glu	tct Ser	gga Gly	tgc Cys 105	aaa Lys	gaa Glu	tgt Cys	gag Glu	gaa Glu 110	ctg Leu	gag Glu	gaa Glu	aaa Lys	aat Asn 115	att Ile	aaa Lys	gaa Glu	ttt Phe	ttg Leu 120	360
cag Gln	agt Ser	ttt Phe	gta Val	cat His 125	att Ile	gtc Val	caa Gln	atg Met	ttc Phe 130	atc Ile	aac Asn	act Thr	tct Ser	402						